Wall Street’s major averages closed Friday's trading session higher, as both the S&P 500 (SP500) and Nasdaq Composite ...

US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Viking Therapeutics VKTX announced that it has initiated the phase III VANQUISH program, evaluating the subcutaneous (SC) ...

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

A new drug, 'MariTide,' developed by Amgen, has shown significant potential in treating obesity, with trial participants losing up to 16% body weight annually.

The once-monthly drug is still under study but could provide added convenience and another option for patients.